Related Experiment Videos
CD4+ T lymphocytes as a primary cellular target for BAT mAb stimulation
A Raiter1, G Rodionov, A Novogrodsky
1Felsenstein Medical Research Center, Tel Aviv University, Sackler School of Medicine, Rabin Medical Center, Beilinson Campus, Petah-Tikva 49100, Israel.
International Immunology
|November 4, 2000
Summary
The monoclonal antibody BAT selectively stimulates CD4+ T cells, promoting immune responses against tumors. This immune stimulation, involving cytokines like IFN-gamma, may lead to tumor eradication by distinct effector cells.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- BAT is a monoclonal antibody (mAb) targeting human Burkitt lymphoma cells.
- BAT exhibits anti-tumor properties in vivo, stimulating lymphocyte proliferation.
- Previous studies suggest T lymphocytes and NK cells mediate BAT's anti-tumor activity.
Purpose of the Study:
- To identify the primary target cell responsible for BAT's stimulatory effects.
- To investigate the in vitro response of purified lymphocyte subpopulations to BAT.
- To elucidate the cellular mechanisms underlying BAT-mediated anti-tumor immunity.
Main Methods:
- Purification of human CD4+ T cells, CD8+ T cells, and CD56+ NK cells.
- In vitro assessment of lymphocyte proliferation and cytokine secretion (IFN-gamma) upon BAT stimulation.
- Flow cytometry (FACS) analysis to detect BAT antigen expression on lymphocytes.
Main Results:
- BAT selectively stimulated proliferation and IFN-gamma secretion in CD4+ T cells.
- FACS analysis confirmed a selective increase in BAT antigen expression on CD4+ T cells cultured with BAT.
- CD4+ T cells are identified as the primary cellular target for BAT's stimulatory activity.
Conclusions:
- BAT primarily targets and stimulates CD4+ T cells in vitro.
- IFN-gamma produced by CD4+ T cells may activate other immune cells for tumor destruction.
- The effector cells mediating tumor eradication might differ from the primary target cells of BAT.